Lang A E
Can J Neurol Sci. 1986 Feb;13(1):42-6. doi: 10.1017/s0317167100035770.
Forty-four adult patients with various forms of dystonia were treated with anticholinergics slowly increased to maximum tolerated doses. Thirty-seven per cent of the 35 idiopathic dystonia patients had a moderate to marked improvement with an average dosage of 21.5 mg of trihexyphenidyl. Younger patients with a shorter duration of dystonia and those who tolerated higher doses tended to benefit most. However there were exceptions to all of these factors. None of the nine patients with symptomatic dystonias improved more than mildly and most had no benefit despite the use of dosages similar to those resulting in improvement in idiopathic dystonia patients. Side effects were common. These often forced drug withdrawal at lower doses than those which might have resulted in improvement. These results suggest that high dose anticholinergics should be the first line of therapy for disabling dystonia.
44例患有各种形式肌张力障碍的成年患者接受了抗胆碱能药物治疗,药物剂量缓慢增加至最大耐受剂量。在35例特发性肌张力障碍患者中,37%的患者在平均服用21.5毫克苯海索的情况下有中度至明显改善。病程较短的年轻患者以及能够耐受较高剂量药物的患者往往受益最大。然而,所有这些因素都有例外情况。9例症状性肌张力障碍患者中,无一例改善程度超过轻度,尽管使用了与特发性肌张力障碍患者改善情况相似的剂量,但大多数患者并无益处。副作用很常见。这些副作用常常迫使在低于可能带来改善的剂量下就停药。这些结果表明,高剂量抗胆碱能药物应作为致残性肌张力障碍的一线治疗方法。